FDA approves first drug offering a functional cure for chronic hepatitis B
FDA approves first drug offering a functional cure for chronic hepatitis B
FDA approves first drug offering a functional cure for chronic hepatitis B
Key points
اہم نکات
मुख्य बातें
- The US Food and Drug Administration has approved bepirovirsen, sold as Hibsago, the first drug that can offer some adults with chronic hepatitis B a functional cure, Yahoo reports.
- In two large phase 3 trials, about 19 percent of patients reached a functional cure, meaning the virus stayed undetectable for at least 24 weeks after stopping all treatment, compared with none on placebo.
- The six-month injection is for certain adults without cirrhosis whose virus is already suppressed on existing antivirals.
- The US Food and Drug Administration has approved bepirovirsen, sold as Hibsago, the first drug that can offer some adults with chronic hepatitis B a functional cure, Yahoo reports.
- In two large phase 3 trials, about 19 percent of patients reached a functional cure, meaning the virus stayed undetectable for at least 24 weeks after stopping all treatment, compared with none on placebo.
- The six-month injection is for certain adults without cirrhosis whose virus is already suppressed on existing antivirals.
- The US Food and Drug Administration has approved bepirovirsen, sold as Hibsago, the first drug that can offer some adults with chronic hepatitis B a functional cure, Yahoo reports.
- In two large phase 3 trials, about 19 percent of patients reached a functional cure, meaning the virus stayed undetectable for at least 24 weeks after stopping all treatment, compared with none on placebo.
- The six-month injection is for certain adults without cirrhosis whose virus is already suppressed on existing antivirals.
The US Food and Drug Administration has approved bepirovirsen, sold as Hibsago, the first drug that can offer some adults with chronic hepatitis B a functional cure, Yahoo reports. In two large phase 3 trials, about 19 percent of patients reached a functional cure, meaning the virus stayed undetectable for at least 24 weeks after stopping all treatment, compared with none on placebo. The six-month injection is for certain adults without cirrhosis whose virus is already suppressed on existing antivirals.
The US Food and Drug Administration has approved bepirovirsen, sold as Hibsago, the first drug that can offer some adults with chronic hepatitis B a functional cure, Yahoo reports. In two large phase 3 trials, about 19 percent of patients reached a functional cure, meaning the virus stayed undetectable for at least 24 weeks after stopping all treatment, compared with none on placebo. The six-month injection is for certain adults without cirrhosis whose virus is already suppressed on existing antivirals.
The US Food and Drug Administration has approved bepirovirsen, sold as Hibsago, the first drug that can offer some adults with chronic hepatitis B a functional cure, Yahoo reports. In two large phase 3 trials, about 19 percent of patients reached a functional cure, meaning the virus stayed undetectable for at least 24 weeks after stopping all treatment, compared with none on placebo. The six-month injection is for certain adults without cirrhosis whose virus is already suppressed on existing antivirals.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।